For just under $10 a month, Fair Value gives investors an edge by cutting through the noise and highlighting where ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Shares of PVH Corp. fell after hours on Wednesday after the Calvin Klein and Tommy Hilfiger parent cut its full-year profit outlook, citing the impact of tariffs on shipments heading into the U.S. The ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

Pride month is here, Bham! We’ve put together a guide of ways to directly join the fight against HIV + support all members of our LGBT+ community—from events to giveaways + more. 👇 NowPartner #bham # ...

The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...